Aridis Pharmaceuticals, Inc. ARDS
At closeNov 2, 2026, 4:00 PM EST
- YTD
- -86.67%
- 1 year
- -89.19%
- Market cap
- 8.91K
- Revenue (ttm)
- 2.99M
- EPS (ttm)
- -0.32
- Shares out
- 36.24M
- Forward P/E
- 1.35
- YTD return
- -86.67%
- 1-year return
- -89.19%
- Volume
- 10
- Avg volume
- 3.33K
- Open
- 0.00145
- Previous close
- 0.0002
- Day's range
- 0.00145 – 0.00145
- 52-week range
- 0.0001 – 0.05
- Beta
- 0.78
- Analysts
- Buy
- Price target
- 10.00 (+4999900.0%)
- Earnings date
- Dec 23, 2024
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 12.29M
- PEG ratio
- -0.01
- Price / sales
- 4.26
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -8.80%
- Free cash flow
- -12.19M
- Total cash
- 1.32M
- Total debt
- 3.95M
- Return on equity
- 0.00%
- Short % of float
- 6.76%
- 50-day average
- 0.2338
- 200-day average
- 0.63715
Analyst view
Consensus: buy
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 23, 2024
Expected Dec 23, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 23, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 2, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 4, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 6, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Sep 13, 2023 | Jun 1, 2023 | 0.00 | 0.33 | — | — |
| Jun 8, 2023 | Mar 1, 2023 | 0.00 | -0.22 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 26, 2023 | HC Wainwright & Co. | main | — | Buy |
| Aug 16, 2022 | Maxim Group | down | Buy | Hold |
| Jul 20, 2021 | HC Wainwright & Co. | main | — | Buy |
| May 15, 2020 | H.C. Wainwright | reit | — | Buy |
| Feb 19, 2020 | Roth Capital | init | — | Buy |
| Dec 30, 2019 | H.C. Wainwright | init | — | Buy |
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aridispharma.com
News
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer 
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer 
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited 
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer 
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit 
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) 
Aridis Provides Corporate Update 
Aridis Provides Corporate Update 
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
Your note
Sign in to keep a note on ARDS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HAMILTON JOHN F | Director | Conversion of Exercise of derivative security | Jun 4, 2023 | 5,000 |
| JAFRI HASAN | Officer | Conversion of Exercise of derivative security | Jun 4, 2023 | 15,100 |
| KURLAND FRED F | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 4, 2023 | 4,000 |
| PATZER ERIC | Officer and Director | Conversion of Exercise of derivative security | Jun 4, 2023 | 714,132 |
| TRUONG VU | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 4, 2023 | 752,353 |
| WINDHAM-BANNISTER SUSAN RICHARDS | Director | Conversion of Exercise of derivative security | Jun 4, 2023 | 5,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 5.91% | 2,140,174 | 751.20K | Mar 30, 2023 |
| Commonwealth Equity Services, LLC | 1.78% | 646,000 | 226.75K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 1.45% | 525,156 | 184.33K | Mar 30, 2023 |
| Roumell Asset Management LLC | 1.23% | 446,588 | 156.75K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.39% | 143,034 | 50.20K | Mar 30, 2023 |
| Vontobel Holding Limited | 0.14% | 50,000 | 17.55K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Starboard Investment Tr-Roumell Opportunistic Value Fd | 1.48% | 446,588 | 156.75K | Feb 27, 2023 |
| Vanguard Total Stock Market Index Fund | 1.29% | 388,959 | 136.52K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 0.43% | 129,177 | 45.34K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.26% | 79,603 | 27.94K | Feb 27, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.23% | 68,450 | 24.02K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.08% | 25,505 | 8.95K | Feb 27, 2023 |